PDA Visual Inspection Forum 2025

Explore innovation in visual inspection at the 26th edition of the annual PDA Visual Inspection Forum!

Visual inspection (VI) continues to be critical to the manufacture and delivery of high-quality injectable medicines. This conference is the top platform for industry and regulatory experts to address and discuss new developments and expectations in the field.

The regulatory and compendial environment continues to rapidly evolve with new and revised guidance, including the U.S. FDA Inspection of Injectable Products for Visible Particulates guidance, updates to USP <1790>, and the EU GMP Annex 1 revision. These new requirements and the correct implementation of VI within the pharmaceutical manufacturing supply chain are among this year’s main topics.

Automated visual inspection (AVI) provides significant benefits when integrated into the manufacturing process, especially for mass-market products or complex biopharmaceutical medicine. Through practical case studies and expert presentations, hear how technological advancements like the use of AI in image analysis and inspection recipe development can offer significant performance improvements for AVI.

Manual inspection remains an important means of monitoring and controlling product quality. It is the most widely used method for visual inspection and continues to be the pharmacopeial reference method. Learn the key elements of a basic inspection and sampling process as well as special considerations for difficult-to-inspect parenteral (DIP) products, including lyophilized, biopharmaceutical, and special packaging type products.

Don’t miss out on the must-attend event in visual inspection!

Program Planning Committee

• Romain Veillon, GSK (Co-Chair)
• Rick Watson, Merck (Co-Chair)
• Rukman De Silva, U.S. FDA
• Robert Miller, Pfizer
• Felix Riehn, Körber
• Andrea Sardella, Stevanato Group
• John Shabushnig, Insight
• Linda Wildling, Takeda